Published in Am J Gastroenterol on May 06, 2014
Pathway-based approaches to the treatment of inflammatory bowel disease. Transl Res (2015) 0.83
Cosmc is an X-linked inflammatory bowel disease risk gene that spatially regulates gut microbiota and contributes to sex-specific risk. Proc Natl Acad Sci U S A (2016) 0.75
Clostridium Difficile Colitis in Trauma Patients - a Global Step by Step Review. Maedica (Buchar) (2015) 0.75
Recent advances in understanding and managing Crohn's disease. F1000Res (2016) 0.75
Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small Intestine. PLoS One (2017) 0.75
Revealing Potential Biomarkers of Functional Dyspepsia by Combining (1)H NMR Metabonomics Techniques and an Integrative Multi-objective Optimization Method. Sci Rep (2016) 0.75
The IBD drug pipeline-ready to deliver? Am J Gastroenterol (2014) 0.75
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. Therap Adv Gastroenterol (2016) 0.75
Inflammatory bowel disease. N Engl J Med (2002) 21.17
Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology (2004) 14.78
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
A simple clinical colitis activity index. Gut (1998) 4.35
Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat (2008) 2.06
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol (1995) 1.85
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut (2005) 1.72
Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology (2006) 1.69
Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med (2007) 1.67
Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol (2005) 1.52
Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis (2009) 1.30
Anti-inflammatory effects of phosphatidylcholine. J Biol Chem (2007) 1.29
Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol (2004) 1.29
Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol (2003) 1.26
Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev (2005) 1.22
Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut (2005) 1.21
Intestinal surfactant-like material. A novel secretory product of the rat enterocyte. J Clin Invest (1989) 1.03
TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol (2009) 0.98
Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut (2005) 0.95
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev (2008) 0.93
Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf (2008) 0.89
Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol (2010) 0.87
The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis. Aliment Pharmacol Ther (2007) 0.86
Phospholipid in UC: novel, safe and works--is it too good to be true? Gastroenterology (2006) 0.85
Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis--a review of three clinical trials. Expert Opin Investig Drugs (2010) 0.83
Reduced hydrophobicity of the colonic mucosal surface in ulcerative colitis as a hint at a physicochemical barrier defect. Int J Colorectal Dis (2011) 0.80
Extracorporeal life support and plasmapheresis in a case of severe polyintoxication. J Emerg Med (2014) 0.79
Oxidative Stress Activates Membrane Ion Channels in Human Biliary Epithelial Cancer Cells (Mz-Cha-1). Anticancer Res (2015) 0.75
Microscopic (collagenous) colitis in a patient with a heart transplant. Endoscopy (2015) 0.75